Priority review designation is typically granted by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. These agencies evaluate applications based on criteria like the severity of the condition, the unmet medical need, and the potential for significant improvement over existing treatments.
